What's Happening?
enGene Therapeutics Inc., a clinical-stage genetic medicines company, announced updated positive results from Cohort 1 of its Phase 2 LEGEND trial for detalimogene voraplasmid, a non-viral gene therapy for high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive
non-muscle invasive bladder cancer (NMIBC). The company plans to initiate a Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) by the end of 2026, with potential approval anticipated in 2027. The updated data, as of October 29, 2026, show improvements across all efficacy endpoints for the pivotal cohort. The complete response (CR) rate at any time improved to 56% from 54%, and the preliminary Kaplan-Meier estimate of duration of response (DoR) of 12 months or greater improved to 43% from 25%. The median duration of complete response is now 10.1 months, up from 8.6 months. The 12-month CR rate also increased to 24% from 13%. Detalimogene continues to demonstrate a favorable tolerability profile, with only 2% of patients experiencing a serious treatment-related adverse event.
Why It's Important?
This development is significant for patients in the U.S. suffering from high-risk BCG-unresponsive NMIBC, a condition with high recurrence rates and limited bladder-preserving treatment options. If approved, detalimogene would be the first and only non-viral plasmid gene therapy suitable for integration into any urology practice setting, potentially expanding access to a new treatment option. The current standard of care, BCG, often leads to recurrence, and patients may face cystectomy (full bladder removal), a life-altering procedure. The favorable tolerability profile and ease of administration of detalimogene could make it a valuable addition, particularly in community urology practices where over 75% of these patients receive care. The FDA's Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, along with its selection for the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program, underscore the urgent unmet medical need and the potential for expedited review and patient access.
What's Next?
enGene expects to initiate the BLA submission by year-end 2026 and aims to complete it in the first half of 2027, with potential FDA approval in 2027. The company is also preparing for commercialization, focusing on broad adoption across community urology practices. An update on the detalimogene plus surfactant bladder rinse cohort is expected in mid-2027. The ongoing LEGEND trial includes additional cohorts to evaluate detalimogene in NMIBC patients naive to BCG treatment, those exposed to BCG but inadequately treated, and those with papillary-only disease, as well as a cohort receiving polidocanol plus detalimogene. These future studies will further expand the understanding of detalimogene's potential applications and efficacy.
Beyond the Headlines
The potential approval of detalimogene represents a broader shift in cancer treatment towards non-viral genetic medicines, offering an alternative to traditional therapies that may have more severe side effects or complex administration requirements. The Dually Derivatized Oligochitosan (DDX) platform, used to develop detalimogene, could pave the way for other gene therapies by overcoming limitations associated with viral-based approaches, such as handling complexities and manufacturing challenges. This innovation could lead to more accessible and user-friendly genetic treatments, potentially transforming how gene therapies are integrated into routine clinical practice. The emphasis on ease of use and handling suggests a strategic focus on practical considerations for widespread adoption, which could significantly impact patient care beyond the initial approval.
